Five Travere Therapeutics Executives Sold Over $51 Million in Stock Together

Regulatory filings showed a cluster of insider sales at Travere Therapeutics disclosed on the same day. CEO Eric Dube sold $25.4 million in shares, EVP Peter Heerma sold $17.8 million, CFO Cline sold $3.1 million, R&D EVP Jula Inrig sold $2.78 million and CLO Elizabeth Reed sold $2.34 million — a combined total above $51 million. Insider sales by a single executive are routine and often tied to scheduled trading plans, but five separate members of the senior leadership team selling simultaneously is a pattern investors typically watch closely. The filings did not include stated reasons for the sales. What is unresolved is whether these were pre-scheduled 10b5-1 transactions or discretionary sales, information not disclosed in the reports reviewed. Investors will look to Travere's next SEC filings for that detail.